RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: alcohol withdrawal syndrome
Accession: DOID:9002735
browse the term
Definition: The symptoms of this medical condition occur following a reduction in alcohol use after a period of excessive use and ranges from such minor symptoms as insomnia and tremulousness to severe complications such as withdrawal seizures and delirium tremens. Although the history and physical examination usually are sufficient to diagnose alcohol withdrawal syndrome, other conditions may present with similar symptoms.
Synonyms: exact_synonym: AWS
G
Bmal1
basic helix-loop-helix ARNT like 1
severity
ISO
mRNA:decreased expression:peripheral blood mononuclear cells (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
G
Clock
clock circadian regulator
severity
ISO
mRNA:decreased expression:peripheral blood mononuclear cells (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
G
Cry1
cryptochrome circadian regulator 1
severity
ISO
mRNA:decreased expression:peripheral blood mononuclear cells (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
G
Cry2
cryptochrome circadian regulator 2
ISO
mRNA:decreased expression:Peripheral blood mononuclear cell (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
no_association treatment
ISO
DNA:SNPs::CYP2C19*2 (681G>A,rs4244285), CYP2C19*3 (636G>A, rs4986893),CYP2C19*17 (-806C>T, rs12248560) (human) DNA:SNP:promoter:CYP2C19*17 (-806C>T,rs12248560)(human) DNA:SNP:cds:CYP2C19*2 (681G>A,rs4244285)(human)
RGD
PMID:27099220 PMID:30325732 PMID:31957548
RGD:401960863 , RGD:401960882 , RGD:401960880
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
G
Drd4
dopamine receptor D4
severity
ISO
DNA:repeats:exon:
RGD
PMID:20359751
RGD:401959612
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
G
Fkbp5
FKBP prolyl isomerase 5
severity
ISO
DNA:SNPs,haplotypes:multiple
RGD
PMID:24603855
RGD:401976481
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
G
Fos
Fos proto-oncogene, AP-1 transcription factor subunit
treatment
IEP
protein:altered expression:brain
RGD
PMID:26727528 PMID:31778691
RGD:405101372 , RGD:405255665
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
G
Gabrg2
gamma-aminobutyric acid type A receptor subunit gamma 2
IEP
mRNA, protein:increased expression:hippocampus (rat)
RGD
PMID:12488536
RGD:402528882
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
G
Ngf
nerve growth factor
ISO
protein:increased expression:plasma
RGD
PMID:8727238
RGD:401976550
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
G
Npy1r
neuropeptide Y receptor Y1
IEP
mRNA:decreased expression:hippocampus, cerebral cortex (rat)
RGD
PMID:20028355
RGD:10448926
NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759
G
Per1
period circadian regulator 1
severity
ISO
mRNA:decreased expression:peripheral blood mononuclear cells (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
G
Per2
period circadian regulator 2
severity
ISO
mRNA:decreased expression:Peripheral blood mononuclear cell (human)
RGD
PMID:20735373
RGD:401976556
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
G
Prl
prolactin
treatment
ISO
RGD
PMID:3816539
RGD:401960110
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
G
Cnr1
cannabinoid receptor 1
ISO
RGD
PMID:11841893
RGD:1626329
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
G
Ngf
nerve growth factor
ISO
protein:increased expression:serum
RGD
PMID:17434673
RGD:401965399
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
G
Ptgs2
prostaglandin-endoperoxide synthase 2
ISO
RGD
PMID:16318954
RGD:5688289
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Slc6a3
solute carrier family 6 member 3
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:27219321
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
G
Cacna1d
calcium voltage-gated channel subunit alpha1 D
susceptibility
IEP
mRNA, protein:increased expression:inferior colliculus (rat)
RGD
PMID:25556199
RGD:152985539
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
G
Drd2
dopamine receptor D2
susceptibility
ISO
DNA:SNP:exon:A>G(human)
RGD
PMID:23238469
RGD:401959213
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
G
Pdyn
prodynorphin
ISO
mRNA:increased expression:brain
RGD
PMID:15869750
RGD:401850576
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
G
Slc29a1
solute carrier family 29 member 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:21283641
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
G
Slc6a3
solute carrier family 6 member 3
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:27219321
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all